<DOC>
	<DOC>NCT01122940</DOC>
	<brief_summary>Mexican healthy volunteers will receive the current form of the drug (under the name of Epamin) as well as Pfizer's compound (Phenytoin). Bioequivalence will be tested.</brief_summary>
	<brief_title>Bioequivalence Study Of Phenytoin Suspension Versus Epamin® In 34 Healthy Volunteers.</brief_title>
	<detailed_description>Bioequivalence</detailed_description>
	<mesh_term>Phenytoin</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive A Body Mass Index (BMI) of 18 to 26.9 kg/m2 or ± 10% variation of the ideal weight; and a total body weight &gt;50 kg (110 lbs) An informed consent document signed and dated by the subject or a legally acceptable representative. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) Any condition possibly affecting drug absorption (eg, gastrectomy) A positive urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Phenytoin</keyword>
	<keyword>Epamin</keyword>
</DOC>